Chairs: M.F. Fey, CH - E. Zucca, CH
Host Chair: F. Cavalli, CH
Over the past twenty five years or so, this course has become a renowned programme for physicians and scientists with an interest in the diagnosis and treatment of haematological cancers. It typically draws participants from most if not all continents and thus allows for a stimulating truly international gathering of colleagues interested in lymphoma and leukaemia. Oncology or haematology trainees are just as welcome as are experienced colleagues looking for a refresher course.
The international faculty, including ICML key note lecturers, will guide us through the complexity of the biology and the most relevant clinical problems in leukaemia and lymphoma, offering plenary lectures, practice-oriented training through case presentations, workshops in small groups and ample discussion slots. Care will be taken to avoid duplications of presentations later scheduled for the Lugano Conference.
The format of the residential course will furthermore offer opportunities for informal exchange of ideas, views and experience among the participants and with the faculty.
The close co-operation between the ESO Course Chairmen and the ICML Committee will assure an optimal co-ordination of the topics between the course and the ICML Congress. As a particular feature the Ascona course will include important topics and presentations that benefit from the smaller format emphasising clinical judgment and individualisation of treatment, thus complementing the presentations typically offered at large and busy conferences.
Attendance to the course will be by registration and will be limited to 80 participants.
We are much looking forward to meeting and working with you at the beautiful campus on Monte Verità near Ascona, in the lovely Italian-speaking South of Switzerland.
Martin F. Fey, MD Emanuele Zucca, MD
Course Chairman Course Chairman
The programme is designed for postgraduate medical doctors at any stage of clinical career who are interested in haematological oncology. A mix of experienced clinicians or pathologists etc., and oncology/haematology trainees is welcome.
Scientists (PhD) are very welcome too, but they should be advised that the course will emphasise clinical aspects rather than basic biology.
• Learn or reinforce knowledge on modern diagnostic tools in haemato-oncology
• Understand the molecular pathology of leukaemia and lymphoma
• Retain the salient clinical features of important lymphoma or leukaemia entities
• Discuss and weigh evidence favouring particular treatment options in haematological oncology
• Learn how to handle complications of treatment for lymphoma and leukaemia
An intensive and interactive course held in co-operation with and preceding the 14th International Conference on Malignant Lymphoma
ORGANISING SECRETARIAT AND REGISTRATION:
European School of Oncology, ESO Bellinzona Office
Piazza Indipendenza 2, 6500 Bellinzona, Switzerland
Ph +41 91 820 0951 or -52 , fx +41 91 820 0953
The course will be held at the Centro Congressi Monte Verità (www.monteverita.org) in Ascona (Southern Switzerland) located on a beautiful hill overlooking Ascona and the Lago Maggiore.
The airport of reference is Lugano. The Malpensa Airport will not be served with transfers.
Transfers will be organised at given times for arrivals on Saturday , 10 June and for departures on Tuesday, 13 June as indicated in the tables below.
After having registered to the course, participants will be offered the option to register to the transfers as well.
Arrivals – Saturday, 10 June
|from airport/station || ||to course venue |
|Lugano airport||13:40||14:40 |
|Lugano railway station||14:40 ||15:00|
|Locarno railway station||13:40 ||14:00|
Departures – Tuesday, 13 June
|from course venue || ||to airport/station |
|Lugano airport ||8:30||9:30 |
|Lugano railway station||8:30||9:30|
|Lugano ICML||8:30||9:40 |
|Locarno railway station||8:30||8:50 |
All participants will be able to print their own certificate on the completion of the online evaluation form.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 15 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are advised to take out their own personal and travel insurance coverage.
HANS WYDER TRAVEL GRANTS
A limited number of Hans Wyder travel grants were available on a competitive basis to:
- Physicians from middle- and low-income countries as defined by The World Bank;
- Physicians under the age of 40;
The application deadline has passed (28 February 2017).
Travel grant recipients will receive a set amount to contribute to their travel and accommodation expenses, whilst registration will be processed directly by the organisers. The following amounts will be refunded by bank transfer after the course:
- EUR 750 for participants coming from Europe, Middle-East and North-Africa;
- EUR 1250 for participants coming from other regions and overseas.
14th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
The ESO course is held in co-operation with the Organising Committee and will precede the 14th ICML (14-17 June 2017, Lugano, Switzerland). The 14th ICML conference will provide the worldwide most important forum for the discussion of all aspects relating to malignant lymphoma.
ICML and the ESO course are two separate events that require registration to one or the other, or both.
For further information please contact email@example.com or visit www.lymphcon.ch
FACULTY (as of May 2017)
J. Bernhard, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
L. Bulliger, Ulm University Medical Centre, Dept. of Internal Medicine III, Ulm, DE
A. Burchert, University Hospital of Giessen and Marburg, Department of Haematology, Oncology and Immunology, Marburg, DE
F. Cavalli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
S. Dirnhofer, University Hospital Basel, Department of Pathology, Basel, CH
C. Driessen, St. Gallen Cantonal Hospital, Department of Medical Oncology, St. Gallen, CH
M. F. Fey, Berne University, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
G. Gaidano, Amedeo Avogadro University of Eastern Piedmont, Division of Haematology, Novara, IT
B. Gerber, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
M. Guckenberger, University Hospital Zurich, Department of Radiation Oncology, Zurich, CH
T.A. Lister, St. Bartholomew's Hospital, Department of Medical Oncology and Haematology, London, UK
G. Merlini, University of Pavia, Department of Molecular Medicine, Pavia, IT
A. Moccia, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
U. Novak, Berne University, Inselspital, Department of Medical Oncology, Berne, CH
A. Ochsenbein, Berne University, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
D. Rossi, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH and Amedeo Avogadro University of Eastern Piedmont, Division of Haematology, Novara, IT
M.A. Shipp, Harvard University, Dana Farber Harvard Cancer Centre, Lymphoma Programme, Boston, US
G. Stuessi, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
Y. Tomonaga, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Zurich, CH
S. Trelle, University of Berne, CTU Berne, Berne, CH
F. van Leeuwen, Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, NL
A. Younes, Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, US
S. Zimmerli, Berne University, Inselspital , Department of Infectiology, Berne, CH
E. Zucca, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
Welcome and introduction to the course
|Basic cancer biology and immunology |
Chair: L. Bullinger, DE
15:150 Basics of molecular cancer biology A. Burchert, DE
|16:15 AML: new treatment approaches beyond 3+7 L. Bullinger, DE|
16:45 New treatment avenues in myelo-proliferative syndromes
A. Burchert, DE
|17:15 ||Coffee break |
|17:45||Workshop sessions I (4 groups, rotating)|
|Group 1 Communication with cancer patients - Balint J. Bernhard, CH|
Group 2 Principles of blood transfusion and case discussion - Auditorium G. Stüssi, CH
Group 3 Fungal infections in immuno-compromised patients - Eranos S. Zimmerli, CH
Group 4 Lymphoma pathology for clinicians (case demonstrations)- Pioda S. Dirnhofer, CH
| 19:30 ||Dinner|
|Workshop sessions II (4 groups, rotating) |
|Group 2 Communication with cancer patients - Balint J. Bernhard, CH |
Group 3 Principles of blood transfusion and case discussion - Auditorium G. Stüssi, CH
Group 4 Fungal infections in immuno-compromised patients - Eranos S. Zimmerli , CH
Group 1 Lymphoma pathology for clinicians (case demonstrations) - Pioda S. Dirnhofer, CH
Chair: T.A. Lister, UK
|10:30 Debate: Myeloma: auto transplants are soon out C. Driessen, CH|
10:50 Debate: Myeloma: auto transplants stand their ground B. Gerber, CH
11:10 Waldenström - new therapeutic approaches G. Merlini, IT
11:30 AL-amyloidosis G. Merlini, IT
Plenary case discussion I Cases from Bern, CH
|Presenters: M.F. Fey - U. Novak, CH|
Discussants: T.A. Lister, UK - A. Younes, US
|14:30||Uncommon non-Hodgkin’s lymphomas |
Chair: T.A. Lister, UK
|14:30 Extranodal lymphomas: frequent rarities F. Cavalli, CH|
15:00 How do I treat very rare lymphomas (Burkitt, 2xhit, grey)
A. Younes, US
15:30 Lymphoma in organ transplant patients G. Gaidano, IT
|16:30 ||Common non-Hodgkin’s lymphomas |
Chair: E. Zucca, CH
16:30 Follicular lymphoma T.A. Lister, UK
17:15 Diffuse large B-cell lymphoma M.A. Shipp, US
|18:00||Workshop sessions III (4 groups, rotating) |
Group 3 Communication with cancer patients - Balint J. Bernhard, CH
|Workshop sessions IV (4 groups, rotating)|
Group 4 Communication with cancer patients - Balint J. Bernhard, CH
|CLL new therapeutic principles in CLL/lymphoma|
Chair: D. Rossi, CH/IT
10:30 Immune checkpoint inhibitors and CAR-T cells A. Ochsenbein, CH
10:50 B cell lymphoid malignancies A. Younes, US
11:30 New CLL therapies: where are we in the land of plenty? D. Rossi, CH/IT
|13:30||Plenary case discussions II Cases from Bellinzona|
Chair: M.F. Fey, CH
|Case presenters: D. Rossi, CH - A. Moccia, CH|
Discussants: M.A. Shipp, US - A. Younes, US
|Coffee break |
|Supportive care |
Chair: F. Cavalli, CH
15:15 Lymphoma survivors and treatment sequelae F. van Leeuwen, NL
Radiation therapy in haemato-oncology
|15:45 Debate: Radiation oncology in haemato-oncology on its way out M.F. Fey, CH|
16:05 Debate: The haemato-oncology radiation oncologist is here to stay
M. Guckenberger, CH
|16:30||Principles of clinical trials |
Chair: F. Cavalli, CH
|16:30 New thoughts on clinical trial design in haemato-oncology S. Trelle, CH|
17:00 Outcome research and economic analyses in haemato-oncology Y. Tomonaga, CH